Vertex Pharmaceuticals Incorporated (VRTX)
$446.83
$5.09
(1.15%)
As on 05-Jun-2026 16:01EDT
Market cap
$113,588 Mln
Revenue (TTM)
$12,255 Mln
P/E Ratio
26.5
P/B Ratio
5.9
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
0.2 %
-
ROCE
19.4 %
-
Industry P/E
--
-
EV/EBITDA
21.7
-
Debt to Equity
0
-
Book Value
$--
-
EPS
$16.9
-
Face value
--
-
Shares outstanding
253,805,417
10 Years Aggregate
CFO
$16,606.24 Mln
EBITDA
$15,617.12 Mln
Net Profit
$14,123.87 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Vertex Pharmaceuticals (VRTX)
| -1.4 | 4.0 | -6.5 | 0.2 | 10.2 | 16.3 | 16.9 |
|
BSE Sensex
| -12.3 | -3.9 | -6.2 | -8.3 | 5.9 | 7.3 | 10.7 |
|
S&P 100
| 5.5 | 2.6 | 8.6 | 24.9 | 22.1 | 13.7 | 14.7 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Vertex Pharmaceuticals (VRTX)
| 12.6 | -1.0 | 40.9 | 31.5 | -7.1 | 7.9 | 32.1 |
|
S&P 100
| 18.7 | 29.0 | 30.8 | -22.1 | 27.6 | 19.3 | 29.5 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Vertex Pharmaceuticals (VRTX)
|
446.8 | 113,588.1 | 12,255.1 | 4,338.3 | 31.7 | 23.7 | 26.5 | 5.9 |
| 303.1 | 40,318.1 | 4,286.9 | 577.2 | 9.8 | 88.2 | 75.7 | 36.7 | |
| 94.2 | 20,422.4 | 819.6 | -1,183.8 | -141.4 | -143.4 | -- | 29.0 | |
| 74.5 | 12,308.8 | 1,057.9 | -326.6 | -16.4 | -58.9 | -- | 25.0 | |
| 183.5 | 30,617.8 | 16,632.0 | 1,385.0 | 14.1 | 22.3 | 22.8 | 5.0 | |
| 47.4 | 18,823.5 | 2,225.0 | -3,194.0 | -143.4 | -38.2 | -- | 2.5 | |
| 163.9 | 16,478.1 | 3,102.4 | 668.6 | 27.4 | 20.9 | 25.2 | 4.8 | |
| 635.5 | 66,620.0 | 14,919.6 | 4,423.4 | 34.9 | 14.2 | 15.5 | 2.1 | |
| 14.8 | 13,613.9 | 0.0 | -872.2 | -- | -287.7 | -- | 24.7 | |
| 549.9 | 23,635.2 | 3,169.8 | 1,287.4 | 51.4 | 20.6 | 20.6 | 4.0 |
Shareholding Pattern
View DetailsAbout Vertex Pharmaceuticals (VRTX)
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic... fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts. Read more
-
Executive Chairman
Dr. Jeffrey Marc Leiden M.D., Ph.D.
-
Executive Chairman
Dr. Jeffrey Marc Leiden M.D., Ph.D.
-
Headquarters
Boston, MA
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Vertex Pharmaceuticals (VRTX)
What is the current share price of Vertex Pharmaceuticals Incorporated (VRTX) Today?
The share price of Vertex Pharmaceuticals Incorporated (VRTX) is $446.83 (NASDAQ) as of 05-Jun-2026 16:01 EDT. Vertex Pharmaceuticals Incorporated (VRTX) has given a return of 10.21% in the last 3 years.
What is the current PB & PE ratio of Vertex Pharmaceuticals Incorporated (VRTX)?
The P/E ratio of Vertex Pharmaceuticals Incorporated (VRTX) is 26.53 times as on 29-May-2026.
The P/B ratio of Vertex Pharmaceuticals Incorporated (VRTX) is 5.87 times as on 29-May-2026, a 32 premium to its peers’ median range of 4.45 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
29.37
|
6.22
|
|
2024
|
-195.86
|
6.39
|
|
2023
|
29.33
|
6.04
|
|
2022
|
22.63
|
5.40
|
|
2021
|
24.10
|
5.59
|
What is the 52 Week High and Low of Vertex Pharmaceuticals Incorporated (VRTX)?
The 52-week high and low of Vertex Pharmaceuticals Incorporated (VRTX) are Rs 507.92 and Rs 362.50 as of 07-Jun-2026.
What is the market cap of Vertex Pharmaceuticals Incorporated (VRTX)?
Vertex Pharmaceuticals Incorporated (VRTX) has a market capitalisation of $ 113,588 Mln as on 29-May-2026. As per SEBI classification, it is a Large Cap company.
Should I invest in Vertex Pharmaceuticals Incorporated (VRTX)?
Before investing in Vertex Pharmaceuticals Incorporated (VRTX), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.